Endeavour Vision

IntelyCare, Inc. provides on-demand staffing services tailored for healthcare organizations, focusing primarily on post-acute care facilities. Established in 2014 and headquartered in Quincy, Massachusetts, the company offers a digital workforce augmentation platform that combines a gig-model application with advanced data science. This platform allows healthcare facilities to optimize staffing levels by efficiently matching nursing professionals with available shifts, thereby addressing the growing gap between workforce supply and demand. Nurses and nursing assistants benefit from the platform by having the flexibility to create their own schedules and select shifts that suit them, promoting a more engaged and productive workforce. IntelyCare serves a variety of clients, including home care agencies, assisted living facilities, long-term care facilities, and rehabilitation hospitals. As a subsidiary of Leerink Revelation Healthcare Fund II GP, LLC, IntelyCare is positioned to revolutionize the healthcare staffing market by filling nursing shifts at a rate three times higher than the industry average.

Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.

Herzsache GmbH provides heart care services to patients at home. Herzsache GmbH is headquartered in Altdorf Bei Nurnberg, Germany.

Virtual Incision is the pioneer of in vivo mini-robot surgery, enabling minimally-invasive colon resection and other abdominal procedures. Colorectal cancer is the second-deadliest form of the disease, and along with conditions like Diverticulitis and Crohn’s, treatment often requires a colectomy, almost 400,000 of which are performed each year in the U.S. alone. Two-thirds of these procedures are still performed open, requiring a long, gruesome incision. VIC’s simpler/easier/cheaper approach is to insert a mini-robot into the insufflated abdomen via a small umbilical incision, after which the highly-dextrous robot arms are freely manipulated at the nearby surgeon console. VIC enables MIS colectomy using well-known laparoscopic tools, onboard vision, and leading multi-quadrant capabilities. After 70+ pig labs and with 60+ patents/applications, VIC is seeking a $15M Series B financing to achieve First-in-Man and prepare for CE Mark and FDA 510(k) submissions.

VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients. Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly cost effective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.

Swift Health Systems Inc. is a medical device company based in Irvine, California, that specializes in developing innovative orthodontic solutions. The company's flagship product, INBRACE, is an invisible orthodontic system designed to correct malocclusion by being discreetly positioned behind the teeth. INBRACE employs patented self-guiding technology that utilizes light and continuous forces to gently adjust teeth, minimizing discomfort and reducing the frequency of doctor visits. FDA registered, INBRACE aims to make orthodontic treatment more appealing by addressing common patient concerns and facilitating practice growth for clinicians. The system integrates digital treatment planning, computer modeling, and direct digital manufacturing to offer a scalable and personalized approach to a wide range of orthodontic cases, thereby raising the standard of care in the field.

Willow is a female technology company that develops an in-bra wearable breast pump. Its breast pumps are cordless and spill-proof. It also tracks milk output through a mobile application along with an online portal, enabling mothers to pump anywhere without hassle. The company was founded in 2014 and is headquartered in Mountain View, California.

CeQur SA focuses on creating innovative insulin delivery systems aimed at improving the management of type 2 diabetes. The company is developing the CeQur Insulin Infuser, a discreet and user-friendly device that allows patients to receive both basal and bolus insulin over a three-day period. This technology helps facilitate intensive insulin therapy, offering individuals flexibility and alleviating the need for multiple daily injections. Founded in January 2008 as a spin-off from Danfoss A/S, CeQur is headquartered in Montreux, Switzerland, with additional operations in Nordborg, Denmark, and Marlborough, Massachusetts. Through its products, CeQur seeks to enhance the quality of life for diabetes patients by simplifying insulin delivery and promoting better adherence to therapy.

Relievant Medsystems, Inc. is a medical device company focused on addressing chronic axial low back pain through a minimally invasive procedure known as Intracept. This innovative treatment specifically targets the basivertebral nerve, utilizing radio-frequency energy delivered through a small access tube into the vertebral body to ablate the nerve. The procedure is performed under real-time fluoroscopic guidance, ensuring precision and safety. Founded in 2004 and headquartered in Minneapolis, Minnesota, with an additional office in Sunnyvale, California, Relievant aims to provide low-risk therapeutic solutions that significantly improve the quality of life for patients suffering from vertebrogenic low back pain.

SOPHiA GENETICS combines deep expertise in life sciences and medical disciplines with mathematical capabilities in data computing. The company aims to bring data analytics solutions to the market, to support healthcare professionals by maximizing the power of data-driven medicine. It achieves this mission through the adoption of SOPHiA AI, which is built using techniques such as statistical inference, pattern recognition, and machine learning. This enables SOPHiA to provide equal benefits to all users, unite experts in a gold standard health-tech platform, and motivate expert knowledge sharing for a sustainable impact on future patients. It contributes to making the global healthcare system more sustainable. By helping healthcare professionals leverage their expertise and work together as a community, patients can receive equal access to better diagnoses and treatments. It combines the first two pillars of data-driven medicine, genomics, and radionics, the company ensures that the data used to help patients. Founded by Jurgi Camblong, Lars Steinmetz, and Pierre Hutter, SOPHiA GENETICS was incorporated in 2011. It has offices in Boston, Massachusetts, Switzerland, and France.

V-Wave Ltd. is a medical technology company based in Caesarea, Israel, with additional offices in the United States. Founded in 2009, it specializes in the development of percutaneous implantable therapeutic devices aimed at treating chronic heart failure (HF) patients, which is a major cause of morbidity and mortality worldwide. The company has created the V-Wave Shunt, a biocompatible inter-atrial unidirectional implant designed for patients with both preserved and reduced ejection fractions, addressing the needs of those who experience disabling symptoms despite optimal medical therapy. V-Wave's innovative approach focuses on relieving symptoms, reducing hospitalizations, enhancing exercise capacity, and improving overall quality of life for HF patients. The organization is backed by a team of experienced engineers and medical scientists who have a proven track record in developing and bringing various implantable cardiovascular devices to market.

Lumeon Ltd. is a digital health company specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and headquartered in London, the company offers a cloud-based platform known as the Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. Lumeon's services encompass business analysis, project management, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon aids healthcare providers in optimizing clinical and administrative workflows, automating tasks, and achieving measurable healthcare outcomes. The company serves a diverse range of clients, including some of Europe's leading healthcare organizations. Lumeon was previously known as Qinec Ltd. before rebranding in July 2016.

Polares Medical S.A. is a medical device company based in Ecublens, Switzerland, with an additional office in Palo Alto, California. The company specializes in developing innovative solutions for patients suffering from mitral valve regurgitation. Its flagship product features a unique trans-catheter mitral valve system that facilitates the replacement of the posterior leaflet with a prosthetic leaflet. This design enables physicians to perform hemi-replacements of the mitral valve, improving coaptation with the native anterior leaflet and offering a less invasive treatment option for patients.

Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.

IntelyCare, Inc. provides on-demand staffing services tailored for healthcare organizations, focusing primarily on post-acute care facilities. Established in 2014 and headquartered in Quincy, Massachusetts, the company offers a digital workforce augmentation platform that combines a gig-model application with advanced data science. This platform allows healthcare facilities to optimize staffing levels by efficiently matching nursing professionals with available shifts, thereby addressing the growing gap between workforce supply and demand. Nurses and nursing assistants benefit from the platform by having the flexibility to create their own schedules and select shifts that suit them, promoting a more engaged and productive workforce. IntelyCare serves a variety of clients, including home care agencies, assisted living facilities, long-term care facilities, and rehabilitation hospitals. As a subsidiary of Leerink Revelation Healthcare Fund II GP, LLC, IntelyCare is positioned to revolutionize the healthcare staffing market by filling nursing shifts at a rate three times higher than the industry average.

Nuvaira, Inc. is a medical device company focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). The company has created a novel, catheter-based Lung Denervation System designed to address airway nerve hyperactivity, a common issue in patients with COPD and asthma. This minimally invasive procedure targets the parasympathetic nerves of the lungs, aiming to enhance lung function, improve exercise capacity, and elevate the quality of life for affected individuals. Founded in 2008 and headquartered in Minneapolis, Minnesota, Nuvaira was previously known as Holaira, Inc. before rebranding in June 2017.

Polares Medical S.A. is a medical device company based in Ecublens, Switzerland, with an additional office in Palo Alto, California. The company specializes in developing innovative solutions for patients suffering from mitral valve regurgitation. Its flagship product features a unique trans-catheter mitral valve system that facilitates the replacement of the posterior leaflet with a prosthetic leaflet. This design enables physicians to perform hemi-replacements of the mitral valve, improving coaptation with the native anterior leaflet and offering a less invasive treatment option for patients.

Relievant Medsystems, Inc. is a medical device company focused on addressing chronic axial low back pain through a minimally invasive procedure known as Intracept. This innovative treatment specifically targets the basivertebral nerve, utilizing radio-frequency energy delivered through a small access tube into the vertebral body to ablate the nerve. The procedure is performed under real-time fluoroscopic guidance, ensuring precision and safety. Founded in 2004 and headquartered in Minneapolis, Minnesota, with an additional office in Sunnyvale, California, Relievant aims to provide low-risk therapeutic solutions that significantly improve the quality of life for patients suffering from vertebrogenic low back pain.

V-Wave Ltd. is a medical technology company based in Caesarea, Israel, with additional offices in the United States. Founded in 2009, it specializes in the development of percutaneous implantable therapeutic devices aimed at treating chronic heart failure (HF) patients, which is a major cause of morbidity and mortality worldwide. The company has created the V-Wave Shunt, a biocompatible inter-atrial unidirectional implant designed for patients with both preserved and reduced ejection fractions, addressing the needs of those who experience disabling symptoms despite optimal medical therapy. V-Wave's innovative approach focuses on relieving symptoms, reducing hospitalizations, enhancing exercise capacity, and improving overall quality of life for HF patients. The organization is backed by a team of experienced engineers and medical scientists who have a proven track record in developing and bringing various implantable cardiovascular devices to market.

Gynesonics, Inc. is a healthcare company specializing in the development of minimally invasive solutions for symptomatic uterine fibroids in women. The company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation to treat these conditions under intrauterine sonography guidance. Founded in 2005, Gynesonics is headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands. The company serves customers worldwide, focusing on providing advanced, incision-free treatment options for uterine conditions.

VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients. Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly cost effective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.

Vertiflex Inc. is a medical device company based in Carlsbad, California, specializing in minimally invasive solutions for lumbar spinal stenosis (LSS). Founded in 2005, the company develops advanced spinal surgery technologies, including the Superion Interspinous Spacer, a titanium implant designed to provide motion preservation and indirect decompression for patients with moderate lumbar spinal stenosis. Additionally, Vertiflex offers the Totalis Direct Decompression System, which includes specialized instruments for performing minimally invasive direct decompression of the lumbar spine. By focusing on procedures that minimize tissue trauma, Vertiflex aims to bridge the gap between conservative care and traditional spine surgery, enhancing treatment options for patients suffering from lumbar stenosis. As of June 2019, Vertiflex operates as a subsidiary of Boston Scientific Corporation.

Chrono Therapeutics Inc., a digital transdermal drug delivery company, develops SmartStop, a digital nicotine replacement therapy. Its wearable solution tailors the timing and dose sizes of drugs, preempts predictable peak disease, and addiction symptoms with a device. The company was incorporated in 2003 and is based in Hayward, California.

EndoStim, Inc., a medical device company, develops and commercializes neurostimulation solutions for the treatment of gastro-esophageal reflux disease (GERD). Its solutions cover treatment for GERD through electrical stimulation. The company distributes its products throughout Europe, Asia, and Latin America. EndoStim was founded in 2009 and is based in Dallas, Texas.

CeQur SA focuses on creating innovative insulin delivery systems aimed at improving the management of type 2 diabetes. The company is developing the CeQur Insulin Infuser, a discreet and user-friendly device that allows patients to receive both basal and bolus insulin over a three-day period. This technology helps facilitate intensive insulin therapy, offering individuals flexibility and alleviating the need for multiple daily injections. Founded in January 2008 as a spin-off from Danfoss A/S, CeQur is headquartered in Montreux, Switzerland, with additional operations in Nordborg, Denmark, and Marlborough, Massachusetts. Through its products, CeQur seeks to enhance the quality of life for diabetes patients by simplifying insulin delivery and promoting better adherence to therapy.

ReShape Medical Inc. is a medical device company specializing in non-surgical weight loss solutions for individuals with mild to moderate obesity, specifically those with a Body Mass Index (BMI) of 30-40. The company offers the ReShape procedure, which utilizes a dual intragastric balloon system combined with a personalized one-year weight loss program, aimed at facilitating weight loss through lifestyle changes. This procedure is designed for adult patients who have not achieved success with diet and exercise alone. ReShape Medical operates through medical weight loss centers and is based in San Clemente, California. Originally founded as Abdominis, Inc. in 2005, the company was rebranded and operates as a subsidiary of ReShape Lifesciences Inc. The broader product portfolio of its parent company includes other minimally invasive devices for treating obesity and metabolic diseases.

Gynesonics, Inc. is a healthcare company specializing in the development of minimally invasive solutions for symptomatic uterine fibroids in women. The company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation to treat these conditions under intrauterine sonography guidance. Founded in 2005, Gynesonics is headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands. The company serves customers worldwide, focusing on providing advanced, incision-free treatment options for uterine conditions.

Kobojo is a French startup that was created in 2008. Kobojo was created to give a social dimension to classical games and online applications, for we love games, most particularly when we can play with friends ! Games for social networks provide much more fun, and a more interesting user experience, for your adversaries are usually people you know ! Kobojo proposes games and applications for social networks, and facilitates the connection between players, for people to play with friends they have not seen for a long time, for instance. Moreover Kobojo’s applications don’t need to be downloaded. Kobojo proposes games for everyone, and despite our games are currently only availabe on Facebook and iPhone, we will soon offer you to play on MySpace, Bebo, Hi5 and many other social networks !

SOPHiA GENETICS combines deep expertise in life sciences and medical disciplines with mathematical capabilities in data computing. The company aims to bring data analytics solutions to the market, to support healthcare professionals by maximizing the power of data-driven medicine. It achieves this mission through the adoption of SOPHiA AI, which is built using techniques such as statistical inference, pattern recognition, and machine learning. This enables SOPHiA to provide equal benefits to all users, unite experts in a gold standard health-tech platform, and motivate expert knowledge sharing for a sustainable impact on future patients. It contributes to making the global healthcare system more sustainable. By helping healthcare professionals leverage their expertise and work together as a community, patients can receive equal access to better diagnoses and treatments. It combines the first two pillars of data-driven medicine, genomics, and radionics, the company ensures that the data used to help patients. Founded by Jurgi Camblong, Lars Steinmetz, and Pierre Hutter, SOPHiA GENETICS was incorporated in 2011. It has offices in Boston, Massachusetts, Switzerland, and France.

Amplidata N.V. offers AmpliStor, an object-based software defined storage solution for enterprise, private cloud, and public cloud implementations in various industries in Belgium and internationally. The company offers Himalaya Service Provider and OEM Edition software, a customizable platform for service provider and OEM-built storage services and solutions; and Himalaya Enterprise Edition software, which provides users with control over their data. It also offers a range of appliances that include the AmpliStor software with servers, as well as controllers and storage nodes connected through a standard switched Ethernet fabric. In addition, the company provides support and professional services for large enterprises, service provides, and distributed government organizations. It offers solutions for cloud services, life sciences, media and entertainment, oil and gas, online applications, digital library, video surveillance, government, and Fortune 500 enterprises. Amplidata N.V. has a strategic partnership with Western Digital Capital. The company was founded in 2008 and is based in Lochristi, Belgium with an additional headquarters in Milpitas, California. It also has support centers in the United States, Belgium, and Taiwan. Amplidata N.V. operates as a subsidiary of HGST Netherlands B.V.

Quid, Inc. is a technology company that has developed a platform designed to search, analyze, and visualize collective intelligence to address strategic questions. Founded in 2006 and headquartered in San Francisco, with additional offices in New York and London, Quid's platform specializes in analyzing text-based data using artificial intelligence and Natural Language Processing. It processes large datasets, including patents, news articles, and blog posts, to identify patterns and insights, facilitating informed decision-making for users in various sectors such as marketing, consulting, technology, healthcare, and financial services. The platform allows non-technical users to independently access valuable information and generate unique insights. In January 2020, Quid merged with NetBase Solutions, combining their strengths under the name Netbase Quid.

Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associes Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization. Oncoethix founders have an unsurpassed track record in identifying and bringing oncology leads to global markets. Dr. Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, irinotecan, oxaliplatin, docetaxel, and trabectedin, first as an academic investigator and then through a specialized oncology clinical research organization. Prior to founding Oncoethix and assuming responsibilities as Chief Operating Officer, Dr. Noel had co-founded another oncology drug development company which in-licensed oxaliplatin as its first portfolio product and subsequently identified, evaluated, and in-licensed novel agents for several clients. Additionally, Dr. Noel has developed expedited registration strategies for many cancer drugs and registration files for a few of these. Dr. Herait managed clinical development of irinotecan, from Phase 1 through Phase 3, while at Rhone Poulenc Rorer and subsequently, as a consultant, managed clinical studies for several novel cancer drugs. Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development. Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.

Spartoo is a European online retailer based in Grenoble, France, specializing in the sale of footwear, apparel, and accessories for men, women, and children. Founded in 2006, the company offers a diverse range of products including trainers, boots, sandals, and various styles of shoes, alongside clothing items such as jeans, coats, and t-shirts. Spartoo serves customers across several countries, including Germany, England, Italy, and Spain, and delivers products to the UK and its offshore islands. The company has developed its own e-commerce platform to facilitate the retail of these fashion items, positioning itself as a key player in the online retail market.

Amplidata N.V. offers AmpliStor, an object-based software defined storage solution for enterprise, private cloud, and public cloud implementations in various industries in Belgium and internationally. The company offers Himalaya Service Provider and OEM Edition software, a customizable platform for service provider and OEM-built storage services and solutions; and Himalaya Enterprise Edition software, which provides users with control over their data. It also offers a range of appliances that include the AmpliStor software with servers, as well as controllers and storage nodes connected through a standard switched Ethernet fabric. In addition, the company provides support and professional services for large enterprises, service provides, and distributed government organizations. It offers solutions for cloud services, life sciences, media and entertainment, oil and gas, online applications, digital library, video surveillance, government, and Fortune 500 enterprises. Amplidata N.V. has a strategic partnership with Western Digital Capital. The company was founded in 2008 and is based in Lochristi, Belgium with an additional headquarters in Milpitas, California. It also has support centers in the United States, Belgium, and Taiwan. Amplidata N.V. operates as a subsidiary of HGST Netherlands B.V.

Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associes Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization. Oncoethix founders have an unsurpassed track record in identifying and bringing oncology leads to global markets. Dr. Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, irinotecan, oxaliplatin, docetaxel, and trabectedin, first as an academic investigator and then through a specialized oncology clinical research organization. Prior to founding Oncoethix and assuming responsibilities as Chief Operating Officer, Dr. Noel had co-founded another oncology drug development company which in-licensed oxaliplatin as its first portfolio product and subsequently identified, evaluated, and in-licensed novel agents for several clients. Additionally, Dr. Noel has developed expedited registration strategies for many cancer drugs and registration files for a few of these. Dr. Herait managed clinical development of irinotecan, from Phase 1 through Phase 3, while at Rhone Poulenc Rorer and subsequently, as a consultant, managed clinical studies for several novel cancer drugs. Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development. Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.

Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies for patients with heart valve diseases, particularly aortic valve stenosis. The company focuses on enhancing patient care and safety by providing simple and accurate solutions for heart valve replacement. Its proprietary Acurate Aortic Valve Replacement System features a distinctive self-positioning design, which facilitates easy implant positioning and alignment, thereby improving the overall ease of use for healthcare providers. Through its advanced transcatheter aortic valve implantation devices, Symetis aims to address severe cardiac valve conditions and enhance treatment options within the healthcare industry.

Amplidata N.V. offers AmpliStor, an object-based software defined storage solution for enterprise, private cloud, and public cloud implementations in various industries in Belgium and internationally. The company offers Himalaya Service Provider and OEM Edition software, a customizable platform for service provider and OEM-built storage services and solutions; and Himalaya Enterprise Edition software, which provides users with control over their data. It also offers a range of appliances that include the AmpliStor software with servers, as well as controllers and storage nodes connected through a standard switched Ethernet fabric. In addition, the company provides support and professional services for large enterprises, service provides, and distributed government organizations. It offers solutions for cloud services, life sciences, media and entertainment, oil and gas, online applications, digital library, video surveillance, government, and Fortune 500 enterprises. Amplidata N.V. has a strategic partnership with Western Digital Capital. The company was founded in 2008 and is based in Lochristi, Belgium with an additional headquarters in Milpitas, California. It also has support centers in the United States, Belgium, and Taiwan. Amplidata N.V. operates as a subsidiary of HGST Netherlands B.V.

Quid, Inc. is a technology company that has developed a platform designed to search, analyze, and visualize collective intelligence to address strategic questions. Founded in 2006 and headquartered in San Francisco, with additional offices in New York and London, Quid's platform specializes in analyzing text-based data using artificial intelligence and Natural Language Processing. It processes large datasets, including patents, news articles, and blog posts, to identify patterns and insights, facilitating informed decision-making for users in various sectors such as marketing, consulting, technology, healthcare, and financial services. The platform allows non-technical users to independently access valuable information and generate unique insights. In January 2020, Quid merged with NetBase Solutions, combining their strengths under the name Netbase Quid.

Kobojo is a French startup that was created in 2008. Kobojo was created to give a social dimension to classical games and online applications, for we love games, most particularly when we can play with friends ! Games for social networks provide much more fun, and a more interesting user experience, for your adversaries are usually people you know ! Kobojo proposes games and applications for social networks, and facilitates the connection between players, for people to play with friends they have not seen for a long time, for instance. Moreover Kobojo’s applications don’t need to be downloaded. Kobojo proposes games for everyone, and despite our games are currently only availabe on Facebook and iPhone, we will soon offer you to play on MySpace, Bebo, Hi5 and many other social networks !

Full-service provider in the prepaid and gift card industry and leading network for the distribution of gift cards in continental Europe.

SmallRivers develops web services that are facilitating the interconnection of people around shared interests. SmallRivers is a privately held startup incorporated in Switzerland (Lausanne) and located on the Swiss Federal Institute of Technology EPFL campus, Scientific Park.

PneumRx, Inc. is a medical device company that specializes in developing minimally invasive treatments for patients with emphysema. Founded in 2004 and headquartered in Mountain View, California, the company is known for its RePneu Lung Volume Reduction Coil, an investigational device aimed at improving the quality of life for individuals suffering from this chronic respiratory condition. PneumRx focuses on addressing unmet medical needs in pulmonary medicine through innovative solutions.

Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies for patients with heart valve diseases, particularly aortic valve stenosis. The company focuses on enhancing patient care and safety by providing simple and accurate solutions for heart valve replacement. Its proprietary Acurate Aortic Valve Replacement System features a distinctive self-positioning design, which facilitates easy implant positioning and alignment, thereby improving the overall ease of use for healthcare providers. Through its advanced transcatheter aortic valve implantation devices, Symetis aims to address severe cardiac valve conditions and enhance treatment options within the healthcare industry.

Amplidata N.V. offers AmpliStor, an object-based software defined storage solution for enterprise, private cloud, and public cloud implementations in various industries in Belgium and internationally. The company offers Himalaya Service Provider and OEM Edition software, a customizable platform for service provider and OEM-built storage services and solutions; and Himalaya Enterprise Edition software, which provides users with control over their data. It also offers a range of appliances that include the AmpliStor software with servers, as well as controllers and storage nodes connected through a standard switched Ethernet fabric. In addition, the company provides support and professional services for large enterprises, service provides, and distributed government organizations. It offers solutions for cloud services, life sciences, media and entertainment, oil and gas, online applications, digital library, video surveillance, government, and Fortune 500 enterprises. Amplidata N.V. has a strategic partnership with Western Digital Capital. The company was founded in 2008 and is based in Lochristi, Belgium with an additional headquarters in Milpitas, California. It also has support centers in the United States, Belgium, and Taiwan. Amplidata N.V. operates as a subsidiary of HGST Netherlands B.V.

Nfocus Neuromedical, Inc. designs, develops, and markets endovascular neurosurgery solutions to cure intracranial aneurysms. The company offers revolutionary systems to treat neurovascular disease, including brain aneurysms. The company was formerly known as CardioVasc, Inc. and changed its name to Nfocus Neuromedical, Inc. in April 2007. The company was incorporated in 1997 and is based in Palo Alto, California. As of February 19, 2013, Nfocus Neuromedical, Inc. operates as a subsidiary of Covidien plc.

BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing targeted and programmable therapeutics known as Accurins. These innovative therapeutics are engineered with specific physical and chemical properties to effectively target particular cells or tissues, allowing for the concentration of therapeutic agents at disease sites. This approach aims to enhance treatment efficacy while reducing adverse effects on healthy tissues. BIND Therapeutics primarily concentrates on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with biopharmaceutical firms to develop Accurins utilizing therapeutic payloads from their pipelines. Its operations extend to the United States and Russia, focusing on targeting tumors at tissue, cellular, and molecular levels.

CXignited is a provider of a cloud-based platform focused on enhancing customer experience through product digitization and authentication. Its ShopCX Cloud Platform integrates shop floor and unified commerce information using RFID, beacons, and IoT technologies. This innovative platform enables luxury retailers and global brands to achieve real-time visibility into in-store engagement, allowing for improved localization, personalization, and overall customer interaction across various channels. Through its Real-time Local Positioning System, CXignited aims to set a new standard in customer experience by effectively connecting products, people, and brand passion.

Spartoo is a European online retailer based in Grenoble, France, specializing in the sale of footwear, apparel, and accessories for men, women, and children. Founded in 2006, the company offers a diverse range of products including trainers, boots, sandals, and various styles of shoes, alongside clothing items such as jeans, coats, and t-shirts. Spartoo serves customers across several countries, including Germany, England, Italy, and Spain, and delivers products to the UK and its offshore islands. The company has developed its own e-commerce platform to facilitate the retail of these fashion items, positioning itself as a key player in the online retail market.

CeQur SA focuses on creating innovative insulin delivery systems aimed at improving the management of type 2 diabetes. The company is developing the CeQur Insulin Infuser, a discreet and user-friendly device that allows patients to receive both basal and bolus insulin over a three-day period. This technology helps facilitate intensive insulin therapy, offering individuals flexibility and alleviating the need for multiple daily injections. Founded in January 2008 as a spin-off from Danfoss A/S, CeQur is headquartered in Montreux, Switzerland, with additional operations in Nordborg, Denmark, and Marlborough, Massachusetts. Through its products, CeQur seeks to enhance the quality of life for diabetes patients by simplifying insulin delivery and promoting better adherence to therapy.

Molecular Partners AG is a clinical-stage biopharmaceutical company based in Schlieren, Switzerland, focused on developing innovative therapies for serious diseases. The company is advancing a new class of small protein therapeutics known as DARPin, exemplified by its lead candidate Abicipar, which is undergoing Phase III clinical trials for wet age-related macular degeneration and diabetic macular edema. Other candidates in development include MP0250, aimed at enhancing standard treatments for multiple myeloma, and MP0274, currently in Phase I trials for HER2-positive solid tumors. Additionally, MP0310 is being evaluated in Phase I trials for immuno-oncology applications, while MPO317 and Peptide-MHC are designed to activate immune responses within tumors. Molecular Partners collaborates with notable partners, including Allergan and Amgen, and is engaged in a program to develop anti-COVID-19 therapeutics in partnership with AGC Biologics. Founded in 2004, the company aims to significantly improve disease management through its cutting-edge therapeutic approaches.

Lumavita AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development and commercialization of innovative anti-infectives aimed at women's health. Founded in 2008, the company offers products such as FemiFect, an antibiotic designed to treat infections associated with vaginitis caused by bacteria, fungi, and protozoa, and SPK-601, which targets human papillomavirus (HPV) and herpes simplex virus (HSV). Lumavita markets its products through various distributors, positioning itself within the expanding biopharmaceutical sector in Switzerland. The company was previously known as Shogoo Pharmaceuticals, AG before rebranding in December 2007 and operates as a subsidiary of Shogoo Pharmaceuticals KK.

CommProve specializes in real-time Quality of Service (QoS) monitoring for wireless networks. Founded in 1996 by experts in network operations and software engineering, the company initially focused on GSM network deployment for Tier 1 customers. This early work revealed the necessity for effective measurement, analysis, and reporting of subscriber experience related to radio link performance. Today, CommProve continues to provide network monitoring, diagnostics, and analytics solutions to enhance the quality of wireless communication services.

Full-service provider in the prepaid and gift card industry and leading network for the distribution of gift cards in continental Europe.

Full-service provider in the prepaid and gift card industry and leading network for the distribution of gift cards in continental Europe.

Molecular Partners AG is a clinical-stage biopharmaceutical company based in Schlieren, Switzerland, focused on developing innovative therapies for serious diseases. The company is advancing a new class of small protein therapeutics known as DARPin, exemplified by its lead candidate Abicipar, which is undergoing Phase III clinical trials for wet age-related macular degeneration and diabetic macular edema. Other candidates in development include MP0250, aimed at enhancing standard treatments for multiple myeloma, and MP0274, currently in Phase I trials for HER2-positive solid tumors. Additionally, MP0310 is being evaluated in Phase I trials for immuno-oncology applications, while MPO317 and Peptide-MHC are designed to activate immune responses within tumors. Molecular Partners collaborates with notable partners, including Allergan and Amgen, and is engaged in a program to develop anti-COVID-19 therapeutics in partnership with AGC Biologics. Founded in 2004, the company aims to significantly improve disease management through its cutting-edge therapeutic approaches.

CXignited is a provider of a cloud-based platform focused on enhancing customer experience through product digitization and authentication. Its ShopCX Cloud Platform integrates shop floor and unified commerce information using RFID, beacons, and IoT technologies. This innovative platform enables luxury retailers and global brands to achieve real-time visibility into in-store engagement, allowing for improved localization, personalization, and overall customer interaction across various channels. Through its Real-time Local Positioning System, CXignited aims to set a new standard in customer experience by effectively connecting products, people, and brand passion.

CXignited is a provider of a cloud-based platform focused on enhancing customer experience through product digitization and authentication. Its ShopCX Cloud Platform integrates shop floor and unified commerce information using RFID, beacons, and IoT technologies. This innovative platform enables luxury retailers and global brands to achieve real-time visibility into in-store engagement, allowing for improved localization, personalization, and overall customer interaction across various channels. Through its Real-time Local Positioning System, CXignited aims to set a new standard in customer experience by effectively connecting products, people, and brand passion.